Scientists Design Trip-Free Psychedelic Treatments That Could Accelerate Mental-Health Research

Researchers have developed a potentially “trip-free” psychedelic that could accelerate research efforts to develop psychedelic-based treatments for mental health. The research focused on a critical part of taking hallucinogens — the psychedelic experience — and whether psychedelics can still be effective at treating mental-health conditions if the psychedelic experience, or “trip,” is eliminated.

Prior research has found that these experiences can be instrumental in helping patients confront painful, uncomfortable memories, and help them gain life-changing insights and realizations.

The “therapy” part of psychedelic-assisted therapy is designed to help people explore the feelings they experienced while under the influence of a psychedelic and apply these insights to their lives. However, psychedelic-assisted therapy often requires one or more trained therapists to be present because the psychedelic experience can last several hours. This significantly increases the costs associated with psychedelic-assisted therapy and limits the number of trained professionals who are available to other patients. Furthermore, many patients aren’t interested in a treatment that involves several hours of “tripping,” regardless of how effective it may be.

Psychedelics also often result in bad trips and can cause negative emotions, including confusion and anxiety, that make the treatment even less desirable to some patients. Consequently, many researchers have been on a quest to develop trip-free psychedelics that would allow patients to derive their mental-health benefits without the need to experience mind-bending effects for several hours.

A nonhallucinogenic psychedelic treatment could significantly reduce treatment time and costs, making the treatment available to a wider market of Americans who desperately need mental health care. Eliminating the trip part of the treatment would also allow treatment centers to handle more patients who don’t require clinical supervision from trained mental-health professionals during the course of treatment.

Although some research has found that the hallucinatory effects of classical psychedelics contribute to their medical efficacy, recent preclinical work has suggested that researchers could potentially disentangle hallucinogens such as magic mushrooms from their therapeutic properties. However, we still don’t have data on how psychedelics interact with signaling pathways and receptors to fully replicate their effects in “trip-free” psychedelics.

Researchers used mouse models to try and understand the signaling pathways psychedelic molecules take once they are consumed. Their findings pointed to the potential development of a nonhallucinogenic psychedelic treatment with the same medical benefits as regular psychedelics.

With millions of Americans failing to find relief from regular mental-health treatments, such a treatment could help to improve the quality of life of countless Americans across the country.

As more companies such as Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) undertake psychedelic drug -development programs, mechanisms may become available for mass access to these novel treatments.

About PsychedelicNewsWire

PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

PsychedelicNewsWire
San Francisco, CA
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicNewsWire.com

PsychedelicNewsWire is powered by IBN